Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anemia of End Stage Renal Disease Clear all
Completed Phase 2 Interventional Results available

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

NCT01630889
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

NCT02273726
View directory record Official record
Conditions
CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin Alfa, Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
74
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 6:16 AM EDT
Terminated Phase 2 Interventional Results available

A Safety Study of Pentoxifylline for the Treatment of Anemia

NCT01102218
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Erythropoietin, Pentoxifylline
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

NCT01414075
View directory record Official record
Conditions
Dialysis, Anemia
Interventions
Roxadustat, Oral Iron, IV Iron
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
3
States / cities
Northridge, California • Yuba City, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 4 Interventional

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

NCT05951192
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic, Renal Anemia
Interventions
Daprodustat
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598442
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
42
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Jul 23, 2026, 6:16 AM EDT
Not listed Not applicable Interventional

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

NCT01017627
View directory record Official record
Conditions
Anemia, Mortality
Interventions
Early anemia diagnosis and treatment, No change from normal routine
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Jul 23, 2026, 6:16 AM EDT
Terminated Phase 2 Interventional

A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD

NCT01873534
View directory record Official record
Conditions
Anemia of Chronic Disease
Interventions
FMX-8
Drug
Lead sponsor
FerruMax Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Arvada, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Jul 23, 2026, 6:16 AM EDT
Not listed Not applicable Interventional

Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model

NCT05936021
View directory record Official record
Conditions
Dialysis
Interventions
Algorithm model-based Aranesp doses, Standard of care
Procedure
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473407
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Renal Failure
Interventions
Epoetin Hospira, Epogen (Amgen)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
84
States / cities
Montgomery, Alabama • Tempe, Arizona • Alhambra, California + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 23, 2026, 6:16 AM EDT
Completed No phase listed Observational

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

NCT01719146
View directory record Official record
Conditions
Anemia of End Stage Renal Disease
Interventions
Specimen collection
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
3
States / cities
Louisville, Kentucky • Springfield, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597753
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin Alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
89
States / cities
Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

NCT02327546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548, Ferrous Sulfate
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473420
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease
Interventions
Epoetin Hospira, Epogen Amgen
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
73
States / cities
Azusa, California • Bakersfield, California • Long Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Jul 23, 2026, 6:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)

NCT00358306
View directory record Official record
Conditions
Acute Renal Failure, Chronic Kidney Failure, Endothelial Dysfunction, Hemolytic-uremic Syndrome (HUS)
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
2 Years to 20 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

NCT02412449
View directory record Official record
Conditions
Healthy
Interventions
AKB-6548 tablet, reference formulation given in the fasted state, AKB-6548 tablet, test formulation given in the fasted state., AKB-6548 tablet, test formulation given in the fed state
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

NCT04410198
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease (ESRD)
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2022 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Results available

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

NCT02243306
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 23, 2026, 6:16 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

NCT01737879
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide, Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

NCT01971164
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia

NCT00236977
View directory record Official record
Conditions
Anemia
Interventions
Venofer, Ferrous Sulfate
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Valley Forge, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Jul 23, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

NCT01147666
View directory record Official record
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 23, 2026, 6:16 AM EDT